Keeping you up to date on recent developments in cardiology, including: What is causing COVID-19 blood clots?; Using machine learning to predict survival rates with OHCA; Remote cardiac rehabilitation proves itself.
Becton, Dickinson and Co. (BD) reported good news Thursday, as it saw quarterly revenues of $4.784 billion for its fourth fiscal quarter, an increase of 4.4% over the prior-year period. Of note, the company’s life sciences segment saw worldwide revenues of $1.488 billion, representing an increase of 31.2% over the prior-year period as reported, or 31.4% on a currency-neutral basis.
Royal Philips NV is reporting the launch of Philips Ventilator Bipap A40 EFL, a noninvasive ventilator that aims to help patients with chronic obstructive pulmonary disease (COPD) breathe easier. With its CE mark in hand, the company has tagged initial target markets as France, Italy and the U.K. Additional European markets are expected to come next year.
Boston Scientific Corp. has scooped up an approval from the U.S. FDA for the Ranger drug-coated balloon to help those with peripheral artery disease in the superficial femoral artery and proximal popliteal artery.
Keeping you up to date on recent developments in cardiology, including: Mobile smartphone tech tied to better clinical outcomes for OHCA; Lung scans for earlier COVID-19 detection; Cholesterol meds affects the organs differently.
Virtual Incision Corp. revealed that it had received a green light from the U.S. FDA to begin its study of its miniaturized in vivo robotic assistant (MIRA) Platform. Initially, the company will focus the platform on minimally invasive laparoscopic colon surgery. With the MIRA Platform, the company will aim to enter a growing market in the U.S., where more than 400,000 colon resection procedures are performed each year.
Day Zero Diagnostics Inc. has reported that data presented at IDWeek highlighted the promise of the company’s new class of diagnostics as it works toward its goal of detecting superbug infections quickly. The company ultimately is hoping to get regulatory signoffs in both the U.S. and Europe for its technology.
Keeping you up to date on recent developments in cardiology, including: Monitoring the hearts of breast cancer patients; Cardiamp demonstrates improvement in heart failure patients; Weight-reduction surgery in severely obese patients could ward off second heart attack.
Edwards Lifesciences Corp. reported good news this week, with its third-quarter results exceeding expectations. Sales came in at $1.1 billion, an increase of 4%, and CEO Mike Mussallem highlighted the success of transcatheter aortic valve replacement (TAVR), with the Sapien valve platform performing well. Mussallem noted that TAVR sales were $745 million, up 6%, with Europe showing strength.
